Genetic characterization of rotavirus A strains circulating in children under 5 years of age with acute gastroenteritis in Tehran, Iran, in 2023-2024: dissemination of the emerging equine- like G3P[8]-I2-E2 DS-1-like strains

被引：0
作者：
Hosseini-Fakhr, Somayeh-Sadat [1 ]
Jalilvand, Somayeh [1 ]
Maleki, Ali [2 ,3 ]
Kachooei, Atefeh [4 ]
Behnezhad, Farzane [4 ]
Mir-Hosseinian, Mahtab [5 ]
Taghvaei, Seiedehparnian [6 ]
Marashi, Sayed Mahdi [1 ]
Shoja, Zabihollah [5 ,7 ]
机构：
[1] Univ Tehran Med Sci, Sch Publ Hlth, Dept Virol, Tehran, Iran
[2] Pasteur Inst Iran, COVID 19 Natl Reference Lab CNRL, Tehran, Iran
[3] Pasteur Inst Iran, Dept Influenza & Resp Viruses, Tehran, Iran
[4] Iran Univ Med Sci, Sch Med, Dept Virol, Tehran, Iran
[5] Pasteur Inst Iran, Dept Virol, Tehran, Iran
[6] Shahid Beheshti Univ Med Sci, Res Inst Childrens Hlth, Pediat Pathol Res Ctr, Tehran, Iran
[7] Pasteur Inst Iran, Res Ctr Emerging & Reemerging Infect Dis, Tehran, Iran
来源：
JOURNAL OF GENERAL VIROLOGY | 2025年 / 106卷 / 03期
关键词：
equine G3 strain; rotavirus; VP4 ANTIGENIC EPITOPES; MOLECULAR CHARACTERIZATION; G3; ROTAVIRUS; VACCINE; EFFICACY; JAPAN; SAFETY; IMMUNOGENICITY; CLASSIFICATION; HETEROGENEITY;
D O I：
10.1099/jgv.0.002088
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
The present study was conducted to monitor the genotype diversity of circulating species A rotavirus (RVA) in Iran. A total of 300 faecal specimens were collected from children under 5years of age hospitalized for acute gastroenteritis between October 2023 and October 2024. G3P[8] represented 72.91% (70/96) of all RVA- positive samples, further subdivided into equine- like G3P[8]-I2-E2 DS- 1- like and human G3P[8]-I1-E1 Wa-like. A retrospective genetic analysis of G3P[8] strains isolated from 2015 to 2017 was also performed and showed that G3P[8] strains belong to the G3P[8]-E1-I1 Wa-like genetic pattern, which is typically similar to human G3P[8] Wa-like strains in this study. The emergence of equine- like G3P[8] DS- 1- like strains in Iran may not be related to selection pressure from rotavirus vaccination, but rather to cross- border migration of rotavirus strains due to population movements.
引用
收藏
页数：12
相关论文
共 70 条
  • [1] Matthijnssens J, Attoui H, Banyai K, Brussaard CP, Danthi P, Et al., ICTV Virus taxonomy profile: Sedoreoviridae 2022, J Gen Virol, 103, (2022)
  • [2] Tate JE, Burton AH, Boschi-Pinto C, Parashar UD, Global, regional, and national estimates of rotavirus mortality in children <5 Years of Age, 2000-2013, Clin Infect Dis, 62, pp. S96-S105, (2016)
  • [3] Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Et al., Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis, N Engl J Med, 354, pp. 11-22, (2006)
  • [4] Vesikari T, Clark HF, Offit PA, Dallas MJ, DiStefano DJ, Et al., Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants, Vaccine, 24, pp. 4821-4829, (2006)
  • [5] Vesikari T, Itzler R, Matson DO, Santosham M, Christie CD, Et al., Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries), Int J Infect Dis, 11, pp. S29-S35, (2007)
  • [6] Meeting of the immunization strategic advisory group of experts, april 2009—conclusions and recommendations, Wkly Epidemiol Rec, 84, pp. 220-236, (2009)
  • [7] Bhandari N, Rongsen-Chandola T, Bavdekar A, John J, Antony K, Et al., Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial, Lancet, 383, pp. 2136-2143, (2014)
  • [8] Chilengi R, Mwila-Kazimbaya K, Chirwa M, Sukwa N, Chipeta C, Immunogenicity and safety of two monovalent rotavirus vaccines, ROTAVAC® and ROTAVAC 5D® in zambian infants, Vaccine, 39, pp. 3633-3640, (2021)
  • [9] Isanaka S, Langendorf C, McNeal MM, Meyer N, Plikaytis B, Et al., Rotavirus vaccine efficacy up to 2 years of age and against diverse circulating rotavirus strains in niger: extended follow-up of a randomized controlled trial, PLoS Med, 18, (2021)
  • [10] Kulkarni PS, Desai S, Tewari T, Kawade A, Goyal N, Et al., A randomized phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants, Vaccine, 35, pp. 6228-6237, (2017)
1234567